Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NGM Biopharmaceuticals
Biotech
NGM to go private as part of $135M buyout by VC firm Column
Following a year that saw a third of staff laid off, NGM Bio has decided to go private as part of a $135 million buyout by The Column Group.
James Waldron
Feb 26, 2024 10:26am
NGM hunts for light at end of tunnel with NASH trial
May 5, 2023 1:13pm
Amarin CEO abruptly resigns—Chutes & Ladders
Apr 7, 2023 9:30am
NGM Bio CEO reveals what led to 33% head count reduction
Apr 5, 2023 9:55am
Merck bails on NGM eye disease collab in wake of trial failure
Dec 21, 2022 9:09am
NGM stock nosedives after Merck-partnered asset fails phase 2
Oct 17, 2022 11:30am